Verition Fund Management
PRVB

Verition Fund Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Verition Fund Management’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-838,716
Closed -$8.87M – 2716
2022
Q4 		$8.87M Sell
838,716
-28,449
-3% -$230K 0.14% 179
2022
Q3 		$3.9M Sell
867,165
-93,298
-10% -$425K 0.04% 538
2022
Q2 		$3.84M Sell
960,463
-126,130
-12% -$598K 0.08% 355
2022
Q1 		$7.95M Sell
1,086,593
-405,971
-27% -$2.43M 0.1% 213
2021
Q4 		$8.39M Buy
1,492,564
+776,835
+109% +$4.93M 0.06% 211
2021
Q3 		$4.58M Buy
715,729
+702,011
+5,117% +$4.51M 0.04% 291
2021
Q2 		$116K Buy
+13,718
New +$111K ﹤0.01% 1699
2020
Q2 		– Sell
-34,124
Closed -$314K – 1194
2020
Q1 		$314K Sell
34,124
-81,613
-71% -$1.05M 0.01% 421
2019
Q4 		$1.72M Sell
115,737
-132,720
-53% -$1.18M 0.03% 295
2019
Q3 		$1.7M Buy
+248,457
New +$2.51M 0.05% 282

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Verition Fund Management's PRVB Position: Q1 2023 in Review

Verition Fund Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2023, closing a stake of 838,716 shares — an estimated $8.87M sold.

Verition Fund Management first reported a position in PRVB in Q3 2019 and held it in 10 quarters. The position peaked at $8.87M in Q4 2022. 182 funds tracked by Wall St. Rank hold PRVB as of Q1 2023.

  • Verition Fund Management reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Verition Fund Management sold 838,716 Provention Bio, Inc. Common Stock shares in Q1 2023, an estimated $8.87M.
  • Verition Fund Management first reported a position in Provention Bio, Inc. Common Stock in Q3 2019 and held it in 10 quarters.
  • Verition Fund Management's Provention Bio, Inc. Common Stock position peaked at $8.87M in Q4 2022.
  • 182 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2023.

Based on Verition Fund Management's 13F filing for Q1 2023, filed 15 May 2023.